<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220929056056N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-26</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Comparative effectiveness of ultra-sound guided injections of corticosteroid and perineural dextrose 5% in patients with cubital tunnel syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparative effectiveness of ultra-sound guided injections of corticosteroid and perineural dextrose 5% on clinical appearance, function, sonographic and electrodiagnostic findings in patients with cubital tunnel syndrome, a clinical trial study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>22</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66117</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly allocated in to two groups by Block Randomization Assignment and Double blind methods. We will have two lists of 11 patients, including the two intervention and control groups, at random. For concealment, method of random sequencing is given to another person who is unaware of the research process, and the questionnaires are completed by a person unaware of the division of groups, Blinding description: Participant: in this study, we does not have the ability to blind the participant because the participant is aware of receiving each intervention. Clinical care giver: we teach the caregiver how to complete the questionnaire. This person is not aware of receiving patient’s intervention. Researcher: this study does not have the ability to blind the researcher due to performing both interventions by himself and being aware of receiving the kind of intervention in each group. The outcome assessor of the complete questionnaires is given to a person who is not aware of the intervention performed and he/she is asked to determine the level of performance in each person according to the questionnaires. Data analyzer: questionnaire are finally given to a person to review the information. This person does not know any of the steps of the work and the way of classification in which the intervention performed.</study_design>
      <phase>2</phase>
      <hc_freetext>Cubital tunnel syndrome.</hc_freetext>
      <i_freetext>Intervention 1: First Intervention group: The patients will be placed in a supine position with the shoulder abducted and the elbow flexed at 90°.The ulnar nerve within the cubital tunnel will be identified in transverse plane, and the injection will be conducted after aseptic preparation. Patients will receive locally 1 ml Methyl Prednisolone Acetate 40 mg and 1 ml Normal saline plus 1 ml Lidocaine 2%, in one session. The patients have to complete the Visual Analog Scale and PRUNE questionnaires before entering the study and 3 and 12 weeks after intervention. Electrodiagnostic and sonographic findings will be evaluated before intervention and 12 weeks later. Intervention 2: Second Intervention group: The patients will be placed in a supine position with the shoulder abducted and the elbow flexed at 90°.The ulnar nerve within the cubital tunnel will be identified in transverse plane, and the injection will be conducted after aseptic preparation. Patients will receive locally 2 ml D5W plus 1 ml Lidocaine 2%, in one session. The patients have to complete the Visual Analog Scale and PRUNE questionnaires before entering the study and 3 and 12 weeks after intervention. Electrodiagnostic and sonographic findings will be evaluated before intervention and 12 weeks later.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All available data can be shared after making people unidentifiable.

When:
Start access period one year after publishing the results.

To whom:
Everyone can access to this information.

Conditions:
If the information in this study helps to improve the science process.

Where to obtain:
Dr. Maryam Mirhadi, 00989177398937, maryam.mirhadii@gmail.com

How to obtain:
After sending the desired message, all authors of the study will be consulted all information will be sent within a maximum of three weeks if permitted.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Mirhadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 5, Yas building, 6 Alley, Ahmad Abad Square, Farhangian Town</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7179871123</zip>
        <telephone>+98 71 3845 4837</telephone>
        <email>maryam.mirhadii@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Mirhadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 5, Yas building, 6 Alley, Ahmad Abad Square, Farhangian Town</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7179871123</zip>
        <telephone>+98 71 3845 4837</telephone>
        <email>maryam.mirhadii@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Mild to moderate ulnar nerve entrapment
Age of 20-65 years
At least 1 month persistence of symptoms and signs</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Severe condition
Brachial plexus neuropathy
History of elbow trauma or operation
Rheumatologic disorder
Peripheral neuropathy
Previous perineural injection
Malignancy
Coagulopathy
Pregnancy
Active infection or infection of injection site</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lesion of ulnar nerve, unspecified upper limb</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First Intervention group: The patients will be placed in a supine position with the shoulder abducted and the elbow flexed at 90°.The ulnar nerve within the cubital tunnel will be identified in transverse plane, and the injection will be conducted after aseptic preparation. Patients will receive locally 1 ml Methyl Prednisolone Acetate 40 mg and 1 ml Normal saline plus 1 ml Lidocaine 2%, in one session. The patients have to complete the Visual Analog Scale and PRUNE questionnaires before entering the study and 3 and 12 weeks after intervention. Electrodiagnostic and sonographic findings will be evaluated before intervention and 12 weeks later.</i_keyword>
      <i_keyword>Second Intervention group: The patients will be placed in a supine position with the shoulder abducted and the elbow flexed at 90°.The ulnar nerve within the cubital tunnel will be identified in transverse plane, and the injection will be conducted after aseptic preparation. Patients will receive locally 2 ml D5W plus 1 ml Lidocaine 2%, in one session. The patients have to complete the Visual Analog Scale and PRUNE questionnaires before entering the study and 3 and 12 weeks after intervention. Electrodiagnostic and sonographic findings will be evaluated before intervention and 12 weeks later.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Upper limb pain. Timepoint: Before intervention, three weeks and twelve weeks later. Method of measurement: Visual Analogue Scale, PRUNE questionnaire.</prim_outcome>
      <prim_outcome>Sensory and Motor symptoms. Timepoint: Before intervention, three weeks and twelve weeks later. Method of measurement: PRUNE questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Function of patient. Timepoint: Before intervention, three weeks and twelve weeks later. Method of measurement: PRUNE questionnaire.</sec_outcome>
      <sec_outcome>Cross-sectional area of ulnar nerve. Timepoint: Before intervention and twelve weeks later. Method of measurement: Ultrasonography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-09-19</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>No 5, Yas building, 6 Alley, Ahmad Abad Square, Farhangian Town Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
